semaglutide and cardiovascular FDA Clears For Cardiac Risk Reduction in Diabetic Patients Semaglutide reduces major cardiovascular events

The aim of this review is to summarise the clinical evidence, including efficacy and safety concerning the use of GLP-1 RAs, and provide practical guidance for clinicians regarding initiation and use of GLP-1 RAs in the treatment of T2D

Her medical history included hypogonadism, growth hormone deficiency, asymptomatic cholecystolithiasis (gallbladder sludge) and obesity

doi: 10.1089/neu.2012.2474 103

Is benign prostatic hyperplasia (BPH) an immune inflammatory disease

Tell your clinician if you have or had any of the following: Personal or family history of medullary thyroid carcinoma or MEN2 Pancreatitis or unexplained severe abdominal pain Significant gastrointestinal disease that limits stomach emptying Pregnancy, plans to become pregnant soon, or breastfeeding Advanced kidney disease or a history of gallbladder disease Use of medications that can cause low blood sugar, which requires coordinated dosing Your care team will review your medical history, current medications, and goals to determine whether semaglutide is suitable or if an alternative plan is safer